Literature DB >> 24763873

Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.

X-Z Sun1, X-Y Tian, D-W Wang, J Li.   

Abstract

AIM: The aim of this study was to investigate the effects of Rho kinase inhibitor-Fasudil on hypoxic pulmonary hypertension (HPH) and pulmonary vascular remodeling in rats.
MATERIALS AND METHODS: A total of 24 Sprague Dawley rats were evenly randomized into control, model and Fasudil intervention groups. Light and transmission electron microscopy were utilized to observe pulmonary vascular remodeling as well as ultrastructural changes in pulmonary arteriole endothelial cells.
RESULTS: The model group showed apparent pulmonary vascular remodeling, pulmonary arteriole endothelial cell injury, the proliferation and swelling of smooth muscle cells around, and the proliferation of collagen fibers. Fasudil intervention improved pulmonary vascular remodeling as well as relieved pulmonary arteriole endothelial cell injury and the proliferation of smooth muscle cells and collagen fibers.
CONCLUSIONS: Fasudil has preventive and reverse effects on HPH, pulmonary vascular remodeling, and pulmonary arteriole endothelial cell injury.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24763873

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

2.  Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.

Authors:  Xiang Zhang; Xueming Zhang; Saihua Wang; Jun Luo; Zhihong Zhao; Changzhu Zheng; Jieyan Shen
Journal:  Can Respir J       Date:  2018-03-26       Impact factor: 2.409

3.  Cyanidin‑3‑O‑β‑glucoside protects against pulmonary artery hypertension induced by monocrotaline via the TGF‑β1/p38 MAPK/CREB signaling pathway.

Authors:  Shao Ouyang; Wei Chen; Zeng Gaofeng; Lei Changcheng; Tian Guoping; Zhu Minyan; Liu Yang; Yang Min; Jiahao Luo
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

4.  Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.

Authors:  Rulin Zhuang; Jinfu Wu; Fang Lin; Lu Han; Xiaoting Liang; Qingshu Meng; Yuyu Jiang; Zhulin Wang; Aixue Yue; Yuying Gu; Huimin Fan; Xiaohui Zhou; Zhongmin Liu
Journal:  Int J Mol Med       Date:  2018-06-13       Impact factor: 4.101

5.  Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery.

Authors:  Priya Muralidharan; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Pharmaceutics       Date:  2021-12-17       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.